Quanta Pharma Retatrutide 50mg Free BW

NEW Now Shipping in 10ml Vials Quanta 50mg Retatrutide has been upgraded to a larger 10ml vial format, giving more headroom for reconstitution and easier, more flexible dosing. Why not try our VLS Retatrutide Pens? Pre-mixed and ready to use - no reconstitution needed �� Currently on sale! 20mg - £150 40mg - £220 Included Free 3ml Bacteriostatic Water with order Janoshik Lab Verified Independent third-party testing 99.84% Purity 62.40mg Actual Content �� Verify at janoshik.com/verify using key: RX4AKSZF838E | Tested: Sept 2025 Quanta Pharma Retatrutide 50mg is a pharmaceutical-grade triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This lyophilised vial from Quanta Pharma offers researchers a high-purity compound for advanced metabolic and weight management studies. Independently lab-verified at 99.84% purity with overfilled content (62.40mg actual). Available for UK delivery with fast dispatch. Quanta Pharma Retatrutide 50mg Specifications Peptide Retatrutide Type Triple Agonist Dosage 50mg/vial Purity 99.84% Form Lyophilised Half-Life ~6 Days Retatrutide 50mg by Quanta Pharma Quanta Pharma Retatrutide Research Benefits Triple receptor action - Targets GLP-1, GIP, and Glucagon receptors for the most comprehensive metabolic research available Superior weight management - Clinical trials showed greater weight reduction compared to dual agonists like Tirzepatide Enhanced fat oxidation - Glucagon receptor activation promotes direct fat burning and energy expenditure Glycemic control - Researched for improving insulin sensitivity and glucose metabolism Extended half-life - Approximately 6 days allows for once-weekly administration in research protocols How Quanta Pharma Retatrutide Works Quanta Pharma Retatrutide is a triple agonist peptide that simultaneously activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the Glucagon receptor. This unique triple-action approach sets it apart from all other incretin-based peptides. The GLP-1 and GIP receptor activation enhances insulin secretion, reduces appetite, and slows gastric emptying. The addition of Glucagon receptor agonism is what makes Quanta Pharma Retatrutide truly unique, as it directly stimulates fat oxidation, increases energy expenditure, and promotes hepatic fat reduction. This three-pronged approach delivers superior metabolic effects in research settings. Quanta Pharma Retatrutide vs Tirzepatide vs Semaglutide Semaglutide targets only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. Quanta Pharma Retatrutide goes further by targeting all three receptors: GLP-1, GIP, and Glucagon. Clinical research has demonstrated that this triple agonist approach produces the most significant weight reduction results of any incretin-based compound studied to date, making Quanta Pharma Retatrutide the most advanced option for metabolic research. Why Choose Quanta Pharma Retatrutide? Quanta Pharma is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. Each vial of Quanta Pharma Retatrutide undergoes rigorous quality control and Janoshik laboratory verification. With confirmed purity of 99.84% and overfilled content at 62.40mg, you can trust that each vial delivers more than what's promised. ⚠️ FOR LABORATORY RESEARCH USE ONLY NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE Safety Classification: - For use by qualified research personnel only - Keep detailed records of usage and storage as per UK research regulations Legal Notice: This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.